Jyong Biotech (MENS) FDA Approvals $1.88 -0.02 (-1.05%) Closing price 04:00 PM EasternExtended Trading$1.87 -0.01 (-0.53%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Jyong Biotech's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Jyong Biotech (MENS). Over the past two years, Jyong Biotech has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as MCS‑8. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. MCS‑8 FDA Regulatory Events MCS‑8 is a drug developed by Jyong Biotech for the following indication: Prostate Cancer Prevention. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - November 20,2025Provided Update Drug: MCS‑8Announced Date: November 20, 2025Indication: Prostate Cancer PreventionAnnouncementJyong Biotech Ltd. announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP).AI SummaryJyong Biotech announced a milestone in developing its plant-derived drug candidate MCS-8 (PCP) after completing statistical analysis of primary efficacy endpoints from its ongoing Phase II trial in Taiwan. The randomized, placebo-controlled study enrolled more than 700 high‑risk men across 20 hospitals and involved over 130 urologists. Participants received two years of treatment with MCS-8 or placebo. Key results showed a 27.3% reduction in overall prostate cancer incidence and a 17.1% reduction in high‑grade prostate cancer (Gleason score ≥ 7) versus placebo. Safety data were favorable: two‑year use did not raise adverse event rates, no serious drug‑related events were reported, and key labs (liver, kidney, glucose, blood pressure) showed no harmful effects. Lipid measures trended better with MCS-8 (TG down, LDL down, HDL up), while fasting glucose rose in the placebo group. Jyong plans to prepare for a global Phase III trial with partners. MCS-8 remains investigational and is not approved for use.Read AnnouncementEnrollment Update - September 16,2025Enrollment Update Phase 2Drug: MCS‑8Announced Date: September 16, 2025Indication: Prostate Cancer PreventionAnnouncementJyong Biotech Ltd. announced that it has completed patient enrollment in its Phase II clinical trial of MCS‑8, an investigational drug candidate for prostate cancer prevention (PCP), with more than 700 high-risk subject who have enrolled into this clinical trial since its commencement.AI SummaryJyong Biotech Ltd., a science-driven biotechnology company in Taiwan, has finished enrolling patients in its Phase II clinical trial of MCS-8, a plant-derived investigational drug for prostate cancer prevention. Since the trial began, more than 700 high-risk subjects have joined the study. This randomized, placebo-controlled trial is taking place at 20 hospitals across Taiwan. Over 130 urologists are involved in testing MCS-8’s ability to prevent prostate tumors in men at high risk. The trial design follows strict protocols to measure safety and preliminary efficacy. The study aims to offer a new preventive therapy for men at risk. Fu-Feng Kuo, the company’s Chairwoman and CEO, said the team exceeded expectations by reaching this milestone despite challenges from the COVID-19 pandemic. MCS-8 remains investigational and is not yet approved. After the treatment period ends, the company will analyze data and share the results as required.Read Announcement Jyong Biotech FDA Events - Frequently Asked Questions Has Jyong Biotech received FDA approval? As of now, Jyong Biotech (MENS) has not received any FDA approvals for its therapy in the last two years. What drugs has Jyong Biotech submitted to the FDA? In the past two years, Jyong Biotech (MENS) has reported FDA regulatory activity for MCS‑8. What is the most recent FDA event for Jyong Biotech? The most recent FDA-related event for Jyong Biotech occurred on November 20, 2025, involving MCS‑8. The update was categorized as "Provided Update," with the company reporting: "Jyong Biotech Ltd. announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP)." What conditions do Jyong Biotech's current drugs treat? Currently, Jyong Biotech has one therapy (MCS‑8) targeting the following condition: Prostate Cancer Prevention. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsAethlon Medical FDA EventsAnixa Biosciences FDA EventsAxsome Therapeutics FDA EventsCapricor Therapeutics FDA EventsEnsysce Biosciences FDA EventsIncyte FDA EventsReplimune Group FDA EventsEli Lilly and Company FDA EventsAgenus FDA EventsAtea Pharmaceuticals FDA EventsKymera Therapeutics FDA EventsLexaria Bioscience FDA EventsMIRA Pharmaceuticals FDA EventsPainReform FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Sutro Biopharma FDA Events Cabaletta Bio FDA Events Arvinas FDA Events Immix Biopharma FDA Events Contineum Therapeutics FDA Events 4D Molecular Therapeutics FDA Events Evolus FDA Events Rezolute FDA Events Ovid Therapeutics FDA Events Prothena FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:MENS last updated on 11/20/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our Partners3 Wall St. Legends Have Same Dark Prediction for June 29thThree Wall Street legends are pointing to the same date - June 29th - as a potential turning point driven by a...TradeSmith | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jyong Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jyong Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - November 20,2025Provided Update Drug: MCS‑8Announced Date: November 20, 2025Indication: Prostate Cancer PreventionAnnouncementJyong Biotech Ltd. announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8 (PCP).AI SummaryJyong Biotech announced a milestone in developing its plant-derived drug candidate MCS-8 (PCP) after completing statistical analysis of primary efficacy endpoints from its ongoing Phase II trial in Taiwan. The randomized, placebo-controlled study enrolled more than 700 high‑risk men across 20 hospitals and involved over 130 urologists. Participants received two years of treatment with MCS-8 or placebo. Key results showed a 27.3% reduction in overall prostate cancer incidence and a 17.1% reduction in high‑grade prostate cancer (Gleason score ≥ 7) versus placebo. Safety data were favorable: two‑year use did not raise adverse event rates, no serious drug‑related events were reported, and key labs (liver, kidney, glucose, blood pressure) showed no harmful effects. Lipid measures trended better with MCS-8 (TG down, LDL down, HDL up), while fasting glucose rose in the placebo group. Jyong plans to prepare for a global Phase III trial with partners. MCS-8 remains investigational and is not approved for use.Read Announcement
Enrollment Update - September 16,2025Enrollment Update Phase 2Drug: MCS‑8Announced Date: September 16, 2025Indication: Prostate Cancer PreventionAnnouncementJyong Biotech Ltd. announced that it has completed patient enrollment in its Phase II clinical trial of MCS‑8, an investigational drug candidate for prostate cancer prevention (PCP), with more than 700 high-risk subject who have enrolled into this clinical trial since its commencement.AI SummaryJyong Biotech Ltd., a science-driven biotechnology company in Taiwan, has finished enrolling patients in its Phase II clinical trial of MCS-8, a plant-derived investigational drug for prostate cancer prevention. Since the trial began, more than 700 high-risk subjects have joined the study. This randomized, placebo-controlled trial is taking place at 20 hospitals across Taiwan. Over 130 urologists are involved in testing MCS-8’s ability to prevent prostate tumors in men at high risk. The trial design follows strict protocols to measure safety and preliminary efficacy. The study aims to offer a new preventive therapy for men at risk. Fu-Feng Kuo, the company’s Chairwoman and CEO, said the team exceeded expectations by reaching this milestone despite challenges from the COVID-19 pandemic. MCS-8 remains investigational and is not yet approved. After the treatment period ends, the company will analyze data and share the results as required.Read Announcement
